Luis A Marcos, Bernard C Camins, David J Ritchie, Ed Casabar, David K Warren
Infectious Diseases Division, Washington University School of Medicine, St Louis, MO 63110-1093, USA. marcoslrz@yahoo.com
The Journal of antimicrobial chemotherapy 2012 MarTo describe the tolerance to long-term telavancin therapy among inpatients as it relates to nephrotoxicity. Retrospective cohort study of adult patients who received telavancin at the Barnes-Jewish Hospital from 1 September 2009 to 1 December 2010. Patients who received less than three doses of telavancin, were on haemodialysis prior to telavancin administration or died within 48 h of initial telavancin administration were excluded. Twenty-one patients received telavancin and met the inclusion criteria. Seven of 21 patients (33%) developed acute renal insufficiency during therapy. Patients who developed acute renal insufficiency had a mean glomerular filtration rate reduction of 56 mL/min/1.73 m(2). In the univariate analysis, high body mass index (P=0.025), use of intravenous contrast dye (P=0.017) and prior serum vancomycin trough levels >20 mg/L (P=0.017) were associated with developing acute renal insufficiency. Two patients required haemodialysis; two had persistent renal insufficiency. Supratherapeutic vancomycin trough levels, high body mass index and receipt of intravenous contrast dye prior to telavancin therapy were associated with acute renal insufficiency.
Luis A Marcos, Bernard C Camins, David J Ritchie, Ed Casabar, David K Warren. Acute renal insufficiency during telavancin therapy in clinical practice. The Journal of antimicrobial chemotherapy. 2012 Mar;67(3):723-6
PMID: 22174040
View Full Text